LeukoDx Chosen as a 2015 Red Herring Europe Winner

TOWSON, MD and JERUSALEM, ISRAEL--(Marketwired - Apr 27, 2015) - Red Herring announced its Red Herring Europe award winners, recognizing Europe's leading private companies and celebrating these startups' innovations and technologies across their respective industries.

Red Herring's Top 100 Europe list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring's editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work.

"Selecting startups that show the most potential for disruption and growth is never easy," said Alex Vieux, publisher and CEO of Red Herring. "We looked at hundreds and hundreds of candidates from all across the continent, and after much thought and debate, narrowed the list down to the Top 100 Winners. Each year, the competition gets tougher but we believe LeukoDx demonstrates the vision, drive and innovation that define a Red Herring Top 100."

Red Herring's editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technological innovation, management quality, and overall business strategy and market penetration. This assessment was complemented by a review of the track records and standings of similar startups in the same verticals, allowing Red Herring to see past the "buzz" and make the list a valuable instrument of discovery and advocacy for the most promising new business models in Europe.

"For LeukoDx this is a sign of recognition that our Accellix automated flow cytometry platform can have a very significant impact on the world of healthcare. We are particularly proud of the fact that LeukoDx was chosen as one of only six life science companies out of the 100 Red Herring Europe Winners," says LeukoDx President & CEO, Julien Meissonnier.

About LeukoDx

LeukoDx's mission is to deliver cost-effective, highly sensitive and actionable diagnostic information at the point of care via a novel automated IVD flow cytometry platform. Founded in 2009, LeukoDx's technology is based on technology initially developed for NASA at CalTech. To date, the Company has developed a compact reader for single use test-specific cartridges, and an application for the rapid identification of sepsis, a condition associated with high morbidity and mortality with no existing rapid diagnostic test.